Inactive Instrument

Gentian Diagnostics AS Share Price Oslo Bors

Equities

NO0010748866

Medical Equipment, Supplies & Distribution

Financials

Sales 2024 * 174M 16.04M 1.28B Sales 2025 * 226M 20.77M 1.65B Capitalization 595M 54.74M 4.36B
Net income 2024 * 7M 644K 51.27M Net income 2025 * 13M 1.2M 95.22M EV / Sales 2024 * 3.05 x
Net cash position 2024 * 63M 5.79M 461M Net cash position 2025 * 65M 5.98M 476M EV / Sales 2025 * 2.35 x
P/E ratio 2024 *
77.6 x
P/E ratio 2025 *
44 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.85%
More Fundamentals * Assessed data
Dynamic Chart
Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024
Gentian Diagnostics Asa Resolves to Elect Ms. Hilja Ibert as Chairperson of the Board of Directors CI
Gentian Diagnostics ASA Appoints Mr. Njaal Kind as Acting CEO CI
Gentian Diagnostics ASA Announces Resignation of Hilja Ibert as CEO, Effective on April 29, 2024 CI
Tomas Settevik Not to Stand for Re-Election as Chairperson of Gentian Diagnostics ASA, Effective April 29, 2024 CI
Gentian Diagnostics' CEO Resigns, Wins Recommendation to Succeed Chair MT
Gentian Diagnostics ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Transcript : Gentian Diagnostics ASA, Q4 2023 Earnings Call, Feb 09, 2024
Gentian Diagnostics Asa Announces Resignation of Frank Frantzen from the Board of Directors CI
Gentian Diagnostics ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Gentian Diagnostics ASA, Q3 2023 Earnings Call, Oct 26, 2023
Gentian Diagnostics ASA Expands Product Portfolio With Turbidimetric Retinol-Binding Protein Immunoassay CI
Gentian Diagnostics ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Gentian Diagnostics ASA, Q2 2023 Earnings Call, Aug 24, 2023
More news
Managers TitleAgeSince
Chief Executive Officer - 15/07/18
Director of Finance/CFO 52 01/01/18
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 64 -
Director/Board Member 44 -
Director/Board Member 60 -
More insiders
Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
Calendar
More about the company